NCT06463093 Differential Diagnosis of Cognitive Disorders of Psychiatric or Neurodegenerative Origin
| NCT ID | NCT06463093 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Central Hospital, Nancy, France |
| Condition | Neurocognitive Disorders |
| Study Type | OBSERVATIONAL |
| Enrollment | 20 participants |
| Start Date | 2024-11-30 |
| Primary Completion | 2025-01-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20 participants in total. It began in 2024-11-30 with a primary completion date of 2025-01-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of the research is to analyze whether 18F-FDG PET helps in the diagnosis and therefore in the management of the patient.
Eligibility Criteria
Inclusion Criteria: * Adult patients with cognitive impairment * Positron emission tomography with flurodeoxyglucose labeled with fluorine 18 carried out in the course of care Exclusion Criteria: * Patients objecting to the collection of their data
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06463093 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Neurocognitive Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06463093 currently recruiting?
Yes, NCT06463093 is actively recruiting participants. Contact the research team at a.verger@chru-nancy.fr for enrollment information.
Where is the NCT06463093 trial being conducted?
This trial is being conducted at Vandœuvre-lès-Nancy, France.
Who is sponsoring the NCT06463093 clinical trial?
NCT06463093 is sponsored by Central Hospital, Nancy, France. The trial plans to enroll 20 participants.